Investor Backing & Capital Strength:
Capital raises and valuation step‑ups are prominent, including a $100M Series D in July 2024 at a reported $2.3B valuation to fund expansion into Medicare Advantage and Medicaid. Independent coverage and company materials corroborate the round and use of proceeds.
Market Expansion:
Nationwide availability (all 50 states + D.C.) and moves into Medicare Advantage (targeted 51 markets by end‑2024) with Medicaid launches planned for 2025 broaden the addressable market. Company updates indicate these government lines are now active in select states.
Strategic Partnerships:
Payer connectivity has accelerated from roughly 40 to 70+ plans with preferred‑network status at major carriers, and revenue scales with completed sessions rather than sign‑ups. These relationships underpin growing patient access and utilization.
